Compare UiPath Inc (PATH) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Pfizer Inc — how do they compare? UiPath Inc trades at $13.59 (market cap $7.26B), while Pfizer Inc trades at $27.88 (market cap $158.39B). The key difference: Pfizer Inc is far larger — about 21.8× UiPath Inc's market cap, and Pfizer Inc pays a 6.19% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| PATH | PFE | |
|---|---|---|
Market Cap | $7.26B | $158.39B |
Sector | Technology | Health |
52-Week High | $19.29 | $29.02 |
52-Week Low | $9.38 | $23.60 |
Enterprise Value | $6.05B | $209.89B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $14.01, down 7.77% amid mixed signals. The stock is near its consensus price target low of $14.00. Revenue growth is improving, with 2025 revenue at $1.43 billion and a projected net profit margin of 21.03% for 2026. Technical indicators show a bearish near-term trend with RSI at oversold levels, while recent news highlights volatility following Q2 earnings.
The outlook is cautious; PATH shows fundamental improvement but faces execution risks and competitive pressure. Analyst consensus is predominantly Hold (70.84%), with a $17.38 price target suggesting modest upside. Key risks include slowing growth guidance and macroeconomic headwinds impacting software demand.
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
